Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Revenue (2023 - 2025)

NewAmsterdam Pharma's Revenue history spans 3 years, with the latest figure at $32000.0 for Q4 2025.

  • For Q4 2025, Revenue fell 99.75% year-over-year to $32000.0; the TTM value through Dec 2025 reached $22.5 million, down 50.61%, while the annual FY2025 figure was $22.5 million, 50.61% down from the prior year.
  • Revenue for Q4 2025 was $32000.0 at NewAmsterdam Pharma, down from $348000.0 in the prior quarter.
  • Across five years, Revenue topped out at $29.1 million in Q3 2024 and bottomed at $32000.0 in Q4 2025.
  • The 3-year median for Revenue is $2.6 million (2023), against an average of $6.8 million.
  • The largest annual shift saw Revenue soared 1490.54% in 2024 before it tumbled 99.75% in 2025.
  • A 3-year view of Revenue shows it stood at $803000.0 in 2023, then skyrocketed by 1490.54% to $12.8 million in 2024, then crashed by 99.75% to $32000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Revenue are $32000.0 (Q4 2025), $348000.0 (Q3 2025), and $19.1 million (Q2 2025).